Clinical Trial

A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A Multicenter, Double-blinded, Randomized, Placebo-controlled Phase 3 Study of ZL-1109 in Chinese Participants with Thyroid Eye Disease (TED)
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-10-01.
Status change: Not Yet Recruiting → Recruiting 2025-12-24
Trial Details
NCT Number NCT07211776
Lead Sponsor Zai Lab (Shanghai) Co., Ltd.
Conditions Thyroid Eye Disease (TED)
Enrollment 99 participants
Start Date 2025-12-05
Primary Completion 2027-03-14 (estimated)
Study Completion 2028-01-29 (estimated)
Updated on ClinicalTrials.gov 2025-12-29